Bluechiip Limited Stock Market Press Releases and Company Profile
Annual Report to Shareholders
Annual Report to Shareholders

Melbourne, Sep 24, 2018 AEST (ABN Newswire) - Bluechiip Ltd (googlechartASX:BCT) provides the Company's Annual Report to shareholders.

2017-18 Highlights

- World-first, highly differentiated technology, with protected IP

- $200M+ growing target market, with very large adjacent markets

- Dramatically increasing partner pipeline, 29 readers sold up from 14 in FY17

- Sale of products $434k, up from $140k in FY17 representing a 209% increase

- Well advanced product development

- Partner opportunity conversion with three executed licence and supply agreements and Bluechiip Enabled products in manufacture

- Growing partner supply, over 250k chips delivered in 2H FY18. Initial repeat revenues with sales up 136% year on year

- Initial $1M order received in Dec 17

- Post year end updated Labcon agreement over $US11.6m ($A15.9m) FY19, 20 and 21

To view the full report, please visit:
http://abnnewswire.net/lnk/44HA6X39


About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 5) (Last 30 Days: 23) (Since Published: 3033)